Corneal ulcer Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | OcuNexus Therapeutics, Recordati Rare Diseases, Santen S.A.S., FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate Pharmaceuticals, Trefoil Therapeutics, A

Corneal ulcer Pipeline constitutes 15+ key companies continuously working towards developing 15+ Corneal ulcer treatment therapies, analyzes DelveInsight.

Corneal ulcer Overview:

A corneal ulcer, also known as keratitis, is an open sore on the cornea, the transparent layer that covers the iris and pupil, similar to how a watch crystal covers a timepiece. While it is typically caused by an eye infection, severe dry eye or other eye conditions can also lead to its development.

A corneal ulcer, which involves damage to the corneal epithelium and the deeper stroma, is a serious eye emergency that can threaten vision. Even with swift treatment, patients may face significant complications, such as corneal scarring, perforation, glaucoma, cataracts, synechiae (adhesions), and vision loss. If bacterial keratitis is left untreated, it can lead to endophthalmitis and, in some cases, loss of the eye.

Download our report @ https://www.delveinsight.com/report-store/corneal-ulcer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Corneal ulcer Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Corneal ulcer Therapeutics Market.

Key Takeaways from the Corneal ulcer Pipeline Report

DelveInsight's Corneal ulcer pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Corneal ulcer treatment.
In March 2025, Glaukos Corporation submitted a New Drug Application (NDA) to the FDA for Epioxa, a non-invasive corneal cross-linking therapy for keratoconus. If approved, this therapy would be the first of its kind.
In January 2025, OKYO Pharma received FDA Investigational New Drug (IND) clearance to proceed with clinical trials of OK-101 for the treatment of corneal neuropathic pain (CNP), a condition that can lead to corneal ulcers. A Phase 2 clinical trial is currently ongoing.
Key Corneal ulcer companies such as OcuNexus Therapeutics, Recordati Rare Diseases, Santen S.A.S., FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate Pharmaceuticals, Trefoil Therapeutics, AmebaGone Inc, Dobecure, Editas medicine, and others are evaluating new drugs for Corneal ulcer to improve the treatment landscape.
Promising Corneal ulcer therapies include Poliesanide, CODA001, Synthetic inhibitors of fibroblast growth factor (FGF), TTHX1114, and others.

Corneal ulcer Pipeline Analysis
The Corneal ulcer pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Corneal ulcer Market.

Categorizes Corneal ulcer therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Corneal ulcer drugs under development based on:

Stage of development

Corneal ulcer Route of administration

Target receptor

Monotherapy vs. combination therapy

Corneal ulcer Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Corneal ulcer Licensing agreements

Funding and investment activities supporting future Corneal ulcer market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/corneal-ulcer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Corneal ulcer Emerging Drugs

Poliesanide: Sifi S.p.A

Poliesanide, being developed by Sifi, is in the phase III stage of development for the treatment of Acanthamoeba Keratitis.

CODA001: OcuNexus Therapeutics

CODA001 is an antisense oligonucleotide that targets the gap junction protein Cx43, which is elevated in persistent epithelial defects. Ormonde et al. reported its first use in five eyes with severe ocular surface burns that did not respond to standard treatments. Delivered via Poloxamer407 gel with amniotic membrane graft or bandage contact lens, the treatment reduced inflammation within 1-2 days and achieved full corneal reepithelialization. Initially developed by CODA Therapeutics, the drug is now being advanced by OcuNexus Therapeutics in phase II.

And more.

Corneal ulcer Companies

Around 15 key companies are developing therapies for Corneal Ulcer, with Sifi S.p.A and others having their drug candidates in the most advanced stage, phase III.

DelveInsight's report covers around 15+ products under different phases of Corneal ulcer clinical trials like

Corneal ulcer Late stage Therapies (Phase III)
Corneal ulcer Mid-stage Therapies (Phase II)
Corneal ulcer Early-stage Therapies (Phase I)
Corneal ulcer Pre-clinical and Corneal ulcer Discovery stage Therapies
Corneal ulcer Discontinued & Inactive Therapies

Corneal ulcer pipeline report provides the Corneal ulcer therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Corneal ulcer Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Corneal ulcer Therapies and Key Corneal ulcer Companies: Corneal ulcer Clinical Trials and recent advancements https://www.delveinsight.com/report-store/corneal-ulcer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Corneal ulcer Pipeline Therapeutic Assessment
• Corneal ulcer Assessment by Product Type
• Corneal ulcer By Stage
• Corneal ulcer Assessment by Route of Administration
• Corneal ulcer Assessment by Molecule Type

Download Corneal ulcer Sample report to know in detail about the Corneal ulcer treatment market @ Corneal ulcer Therapeutic Assessment https://www.delveinsight.com/sample-request/corneal-ulcer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Corneal ulcer Current Treatment Patterns
4. Corneal ulcer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Corneal ulcer Late-Stage Products (Phase-III)
7. Corneal ulcer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Corneal ulcer Discontinued Products
13. Corneal ulcer Product Profiles
14. Corneal ulcer Key Companies
15. Corneal ulcer Key Products
16. Dormant and Discontinued Products
17. Corneal ulcer Unmet Needs
18. Corneal ulcer Future Perspectives
19. Corneal ulcer Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Corneal ulcer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/corneal-ulcer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.